

# Naomi Serling-Boyd

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5285546/publications.pdf>

Version: 2024-02-01

31  
papers

1,024  
citations

686830

13  
h-index

454577

30  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1497  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US "hot spot". <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1156-1162.	0.5	217
2	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.5	151
3	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	2.8	86
4	Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 660-666.	0.5	74
5	Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 289-291.	0.5	69
6	Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. <i>Arthritis and Rheumatology</i> , 2021, 73, 374-380.	2.9	66
7	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.5	49
8	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e855-e864.	2.2	38
9	SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 817-819.	0.5	37
10	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	1.8	34
11	The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152010.	1.6	32
12	Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e638-e647.	2.2	30
13	Recent advances in the diagnosis and management of giant cell arteritis. <i>Current Opinion in Rheumatology</i> , 2020, 32, 201-207.	2.0	24
14	Incident systemic rheumatic disease following COVID-19. <i>Lancet Rheumatology, The</i> , 2021, 3, e402-e404.	2.2	17
15	The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1.3-2.	0.5	14
16	Gastric antral vascular ectasia in systemic sclerosis: Association with anti-RNA polymerase III and negative anti-nuclear antibodies. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 938-942.	1.6	9
17	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2022, 49, 110-114.	1.0	9
18	Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy. <i>RMD Open</i> , 2022, 8, e002082.	1.8	9

#	ARTICLE	IF	CITATIONS
19	Using electronic visits (E-visits) to achieve goal serum urate levels in patients with gout in a rheumatology practice: A pilot study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1382-1386.	1.6	8
20	Response to: "Correspondence on "SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease" by C<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e131-e131.	0.5	8
21	Assessing the Severity of <scp>COVID</scp>â€19 Lung Injury in Rheumatic Diseases Versus the General Population Using Deep Learningâ€Derived Chest Radiograph Scores. <i>Arthritis Care and Research</i> , 2023, 75, 657-666.	1.5	8
22	Enhancing the Inpatient Consultation Learning Environment to Optimize Teaching and Learning. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 73-83.	0.8	7
23	Expert Perspective: Management of Antineutrophil Cytoplasmic Antibodyâ€Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 1305-1317.	2.9	6
24	Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study. <i>Journal of Rheumatology</i> , 2022, 49, 104-109.	1.0	5
25	Response to: "COVID-19 in patients with rheumatological diseases treated with Anti-TNFâ€ by Brito et al and "Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China â€hot spotâ€ versus in US â€hot spotâ€: similarities and differencesâ€ by Zhao et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e64-e64.	0.5	4
26	Response to: "COVID-19 in patients with rheumatic diseases: what is the real mortality risk?"â€ by Marques<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e135-e135.	0.5	3
27	A case of antisynthetase syndrome with thrombotic thrombocytopenic purpura. <i>Rheumatology</i> , 2021, 60, e143-e145.	0.9	2
28	An 80â€Yearâ€Old Man With Fevers, Altered Mental Status, and Joint Effusions. <i>Arthritis Care and Research</i> , 2020, 72, 293-300.	1.5	1
29	Response to: "Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitorsâ€ by Jovani<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e132-e132.	0.5	1
30	Management of primary vasculitides with biologic and novel small molecule medications. <i>Current Opinion in Rheumatology</i> , 2021, 33, 8-14.	2.0	1
31	The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial. <i>Rheumatology and Therapy</i> , 2022, 9, 497-508.	1.1	1